Study · Randomized controlled trial · n = 1,091 · 2009

8 results

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR

Diabetes care17 Oct 2008Cited by 849 (Europe PMC)

PMID18931095PMCIDPMC2606836DOI10.2337/dc08-1355PepBankPUB-18931095

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide 1.8 mg reduced A1C versus placebo.
In plain wordsIn adults with type 2 diabetes on metformin, liraglutide 1.8 mg lowered A1C more than placebo.
Peptide
Liraglutide
Outcome
DecreaseA1C reduction, 1.8 mg
Study
n = 1,091
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg/day · subcutaneous · 26 weeksAs given in this study (human).
Measurements
A1C decrease
1%
liraglutide 1.8 mg
A1C change
0.1%
placebo (increase)
Source sentences
Summary
A1C values were significantly reduced in all liraglutide groups versus the placebo group (P < 0.0001) with mean decreases of 1.0% for 1.8 mg liraglutide, 1.2 mg liraglutide, and glimepiride and 0.7% for 0.6 mg liraglutide and an increase of 0.1% for placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected subcutaneously), to placebo, or to glimepiride (4 mg once daily). All treatments wer…
Report a problemFND-1893109501
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide 1.2 mg reduced A1C versus placebo.
In plain wordsIn adults with type 2 diabetes on metformin, liraglutide 1.2 mg lowered A1C more than placebo.
Peptide
Liraglutide
Outcome
DecreaseA1C reduction, 1.2 mg
Study
n = 1,091
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg/day · subcutaneous · 26 weeksAs given in this study (human).
Measurements
A1C decrease
1%
liraglutide 1.2 mg
A1C change
0.1%
placebo (increase)
Source sentences
Summary
A1C values were significantly reduced in all liraglutide groups versus the placebo group (P < 0.0001) with mean decreases of 1.0% for 1.8 mg liraglutide, 1.2 mg liraglutide, and glimepiride and 0.7% for 0.6 mg liraglutide and an increase of 0.1% for placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected subcutaneously), to placebo, or to glimepiride (4 mg once daily). All treatments wer…
Report a problemFND-1893109502
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, liraglutide 0.6 mg reduced A1C versus placebo.
In plain wordsIn adults with type 2 diabetes on metformin, liraglutide 0.6 mg lowered A1C more than placebo.
Peptide
Liraglutide
Outcome
DecreaseA1C reduction, 0.6 mg
Study
n = 1,091
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg/day · subcutaneous · 26 weeksAs given in this study (human).
Measurements
A1C decrease
0.7%
liraglutide 0.6 mg
A1C change
0.1%
placebo (increase)
Source sentences
Summary
A1C values were significantly reduced in all liraglutide groups versus the placebo group (P < 0.0001) with mean decreases of 1.0% for 1.8 mg liraglutide, 1.2 mg liraglutide, and glimepiride and 0.7% for 0.6 mg liraglutide and an increase of 0.1% for placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected subcutaneously), to placebo, or to glimepiride (4 mg once daily). All treatments wer…
Report a problemFND-1893109503
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on metformin, body weight decreased in all liraglutide groups compared with an increase in the glimepiride group.
In plain wordsIn adults with type 2 diabetes on metformin, weight fell on liraglutide but rose on glimepiride.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 1,091
Comparator
Glimepiride
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6, 1.2 or 1.8 mg/day · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Weight decrease
1.8 to 2.8 kg
liraglutide groups
Weight increase
1 kg
glimepiride
Source sentences
Summary
Body weight decreased in all liraglutide groups (1.8-2.8 kg) compared with an increase in the glimepiride group (1.0 kg; P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected subcutaneously), to placebo, or to glimepiride (4 mg once daily). All treatments wer…
Report a problemFND-1893109504
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, the incidence of minor hypoglycemia with liraglutide was comparable to placebo.
In plain wordsIn adults with type 2 diabetes on metformin, minor low blood sugar was about as common with liraglutide as with placebo.
Peptide
Liraglutide
Outcome
No significant changeMinor hypoglycemia versus placebo
Study
n = 1,091
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.6, 1.2 or 1.8 mg/day · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Minor hypoglycemia incidence
3%
liraglutide (approximate)
Source sentences
Summary
The incidence of minor hypoglycemia with liraglutide ( approximately 3%) was comparable to that with placebo
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected subcutaneously), to placebo, or to glimepiride (4 mg once daily). All treatments wer…
Report a problemFND-1893109505
06HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, minor hypoglycemia was less frequent with liraglutide than with glimepiride.
In plain wordsIn adults with type 2 diabetes on metformin, minor low blood sugar was less common with liraglutide than with glimepiride.
Peptide
Liraglutide
Outcome
DecreaseMinor hypoglycemia versus glimepiride
Study
n = 1,091
Comparator
Glimepiride
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.6, 1.2 or 1.8 mg/day · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Minor hypoglycemia incidence
3%
liraglutide (approximate)
Minor hypoglycemia incidence
17%
glimepiride
Source sentences
Summary
The incidence of minor hypoglycemia with liraglutide ( approximately 3%) was comparable to that with placebo but less than that with glimepiride (17%; P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected subcutaneously), to placebo, or to glimepiride (4 mg once daily). All treatments wer…
Report a problemFND-1893109506
07HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, nausea was reported more often with liraglutide than in the placebo and glimepiride groups.
In plain wordsIn adults with type 2 diabetes on metformin, nausea was more common with liraglutide than with placebo or glimepiride.
Peptide
Liraglutide
Outcome
IncreaseNausea
Study
n = 1,091
Comparator
Placebo and glimepiride (reported together)
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.6, 1.2 or 1.8 mg/day · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Nausea incidence
11 to 19%
liraglutide
Nausea incidence
3 to 4%
placebo and glimepiride
Source sentences
Summary
Nausea was reported by 11-19% of the liraglutide-treated subjects versus 3-4% in the placebo and glimepiride groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected subcutaneously), to placebo, or to glimepiride (4 mg once daily). All treatments wer…
Report a problemFND-1893109507
08HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on metformin, the incidence of nausea with liraglutide declined over time.
In plain wordsIn adults with type 2 diabetes on metformin, nausea with liraglutide became less common over time.
Peptide
Liraglutide
Outcome
DecreaseNausea incidence over time
Study
n = 1,091
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.6, 1.2 or 1.8 mg/day · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
The incidence of nausea declined over time.
1 context sentence(design, population, supporting numbers)
Summary · context
In this 26-week, double-blind, double-dummy, placebo- and active-controlled, parallel-group trial, 1,091 subjects were randomly assigned (2:2:2:1:2) to once-daily liraglutide (either 0.6, 1.2, or 1.8 mg/day injected subcutaneously), to placebo, or to glimepiride (4 mg once daily). All treatments wer…
Report a problemFND-1893109508

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT04529278

Efficacy and Tolerance of Liraglutide for Weight Loss in Obese Type 2 Diabetic Hemodialysis Patients

Fondation Hôpital Saint-Josephn = 1818 Jan 2021 to est. 31 Dec 2023

Diabetes Mellitus, Type 2 · Hemodialysis · Obese

Trial page ClinicalTrials.govUpdated 14 Apr 2023

Status unknownPhase 3NCT03421119

Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes

Cinnagenn = 300est. 20 Jun 2019 to est. 1 Dec 2019

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 6 Feb 2019

Status unknownNot applicableNCT02930265

Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy

Chinese PLA General Hospitaln = 400Sept 2016 to est. Mar 2018

Ischemic Cardiomyopathy

Trial page ClinicalTrials.govUpdated 12 Oct 2016

CompletedPhase 3Results postedNCT00318461

To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together

Novo Nordisk A/Sn = 1,091May 2006 to Nov 2008

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 7 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.